The Effect of Clinical Characteristics and Subtypes on Amyloid Positivity in Patients with Amnestic Mild Cognitive Impairment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: Mild cognitive impairment (MCI) is a prodromal stage of dementia. Amyloid deposits in positron-emission tomography (PET) imaging of MCI patients imply a higher risk for advancing to dementia, with rates of 10%–15% yearly. The purpose of this study was to investigate the clinical characteristics of subgroups of amnestic MCI (aMCI) that may have a higher impact on amyloid positivity. Methods: We recruited 136 aMCI patients. All patients underwent a 20-minute F-18 florbetaben or flutemetamol PET scan. We classified amyloid PET images as positive or negative according to a semi-quantitative method. We evaluated the amyloid positivity of subgroups of aMCI (early vs. late type, single vs. multiple amnestic type, verbal vs. verbal, and visual amnestic type), and compared baseline clinical characteristics including key risk factors, apolipoprotein E4 (apoE4) genotype, and neuropsychological assessments with amyloid positivity in aMCI. Results: The amyloid positivity in total aMCI was 41%. The positivity rate according to subgroup of aMCI were as follow: Late aMCI (49%) vs. early aMCI (33%) (p=0.13), multiple aMCI (40%) vs. single aMCI (38%) (p=0.51), and verbal and visual aMCI (59%) vs. verbal aMCI (35%) (p=0.01), respectively. The mean age and the frequency of apoE4 allele of the amyloidpositive group was higher than that of the amyloid-negative group in aMCI (p<0.01). Conclusions: We found that the amyloid positivity was related to patterns of clinical subtypes, characteristics, and risk factors in patients with aMCI.
Abstract
Background and Purpose: Mild cognitive impairment (MCI) is a prodromal stage of dementia. Amyloid deposits in positron-emission tomography (PET) imaging of MCI patients imply a higher risk for advancing to dementia, with rates of 10%–15% yearly. The purpose of this study was to investigate the clinical characteristics of subgroups of amnestic MCI (aMCI) that may have a higher impact on amyloid positivity. Methods: We recruited 136 aMCI patients. All patients underwent a 20-minute F-18 florbetaben or flutemetamol PET scan. We classified amyloid PET images as positive or negative according to a semi-quantitative method. We evaluated the amyloid positivity of subgroups of aMCI (early vs. late type, single vs. multiple amnestic type, verbal vs. verbal, and visual amnestic type), and compared baseline clinical characteristics including key risk factors, apolipoprotein E4 (apoE4) genotype, and neuropsychological assessments with amyloid positivity in aMCI. Results: The amyloid positivity in total aMCI was 41%. The positivity rate according to subgroup of aMCI were as follow: Late aMCI (49%) vs. early aMCI (33%) (p=0.13), multiple aMCI (40%) vs. single aMCI (38%) (p=0.51), and verbal and visual aMCI (59%) vs. verbal aMCI (35%) (p=0.01), respectively. The mean age and the frequency of apoE4 allele of the amyloidpositive group was higher than that of the amyloid-negative group in aMCI (p<0.01). Conclusions: We found that the amyloid positivity was related to patterns of clinical subtypes, characteristics, and risk factors in patients with aMCI.
참고문헌 (25)
- Gauthier S, "Mild cognitive impairment", Lancet, 367, pp.1262~1270 (2006)
- Petersen RC, "Mild cognitive impairment as a diagnostic entity", J Intern Med, 256, pp.183~194 (2004)
- Tomadesso C, "Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients", Alzheimers Dement (Amst), 10, pp.269~277 (2018)
- Petersen RC, "Mild cognitive impairment: an overview", CNS Spectr, 13, pp.45~53 (2008)
- Sabri O, "Beta-amyloid imaging with florbetaben", Clin Transl Imaging, 3, pp.13~26 (2015)
- Wolk DA, "Amyloid imaging in mild cognitive impairment subtypes", Ann Neurol, 65, pp.557~568 (2009)
- Bennett DA, "Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions", Neurology, 64, pp.834~841 (2005)
- Mufson EJ, "Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment", Exp Neurol, 158, pp.469~490 (1999)
- Landau SM, "Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI", Neurology, 86, pp.1377~1385 (2016)
- de Leon MJ, "Early marker for Alzheimer's disease: the atrophic hippocampus", Lancet, 2, pp.672~673 (1989)
- Jack CR Jr, "Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment", Neurology, 52, pp.1397~1403 (1999)
- De Santi S, "Hippocampal formation glucose metabolism and volume losses in MCI and AD", Neurobiol Aging, 22, pp.529~539 (2001)
- Chételat G, "Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?", Neurology, 60, pp.1374~1377 (2003)
- Karas GB, "Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease", Neuroimage, 23, pp.708~716 (2004)
- Korf ES, "Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment", Neurology, 63, pp.94~100 (2004)
- Zhang S, "Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment", Int J Clin Pract, 66, pp.185~198 (2012)
- Stoub TR, "MRI predictors of risk of incident Alzheimer disease: a longitudinal study", Neurology, 64, pp.1520~1524 (2005)
- Park JH, "Memory performance on the story recall test and prediction of cognitive dysfunction progression in mild cognitive impairment and Alzheimer's dementia", Geriatr Gerontol Int, 17, pp.1603~1609 (2017)
- Kang Y, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Morris JC, "The Clinical Dementia Rating (CDR): current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Fouty HE, "Content validity of the geriatric depression scale in inpatient health care settings", GSTF J Psychol, 3, pp.7~9 (2016)
- Petersen RC, "Vitamin E and donepezil for the treatment of mild cognitive impairment", N Engl J Med, 352, pp.2379~2388 (2005)
- Vega JN, "Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments", Curr Psychiatry Rep, 16, pp.490~ (2014)
- Molano J, "Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study", Brain, 133, pp.540~556 (2010)
- Patterson BW, "Age and amyloid effects on human central nervous system amyloid-beta kinetics", Ann Neurol, 78, pp.439~453 (2015)